A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors

NCT03503604 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

BIOLOGICAL: hPV19 mAb
BIOLOGICAL: hPV19 mAb
DRUG: 5-Fluorouracil
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Irinotecan

Sponsor

SuZhou Stainwei Biotech Inc.